Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo once every three weeks for up to nine doses, along with an infusion of Keytruda once ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

the antibody in its blockbuster cancer immunotherapy Keytruda. They found that the new version was more stable and suitable for subcutaneous injection. Earlier this year, meanwhile, another team ...

A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

2017. Raval AN and Pepine CJ. Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting, Cardiovasc Revasc Med, 2021. CONTACT: Media Contact: Miranda Peto, ...